Ibrutinib in CLL/SLL: From bench to bedside (Review)

  • Authors:
    • Fuming Zi
    • Li Yu
    • Qingzhi Shi
    • Aiping Tang
    • Jing Cheng
  • View Affiliations

  • Published online on: October 10, 2019     https://doi.org/10.3892/or.2019.7364
  • Pages: 2213-2227
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

B-cell receptor (BCR) signaling is important for the development and maturation of normal B-cells and plays a key role in B-cell malignancies. Bruton's tyrosine kinase (BTK), a crucial terminal kinase enzyme in BCR signaling, has emerged as an attractive target and has been successfully applied in the treatment of hematological malignancies. Ibrutinib, a BTK inhibitor, has demonstrated marked efficacy and tolerability in treatment-naïve, relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma (MCL). Ibrutinib has been approved by the Food and Drug Administration (FDA) for the treatment of CLL/SLL, MCL, marginal zone lymphoma and Waldenström macroglobulinemia and by the China FDA for the treatment of CLL/SLL and MCL. Clinical trials of ibrutinib, as a single agent or combined with chemoimmunotherapy and other promising novel agents in the treatment of B-cell malignancy therapy, such as diffuse large B-cell lymphoma, follicular lymphoma, multiple myeloma, primary and secondary CNS lymphoma and acute lymphoblastic leukemia, T-cell lymphoma and myelodysplastic syndrome, are ongoing (https://clinicaltrials.gov/). The aim of the present review was mainly to cover the clinical developments regarding the use of ibrutinib in the treatment of CLL/SLL, as well as its safety and toxicity profile.

Related Articles

Journal Cover

December 2019
Volume 42 Issue 6

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Zi, F., Yu, L., Shi, Q., Tang, A., & Cheng, J. (2019). Ibrutinib in CLL/SLL: From bench to bedside (Review). Oncology Reports, 42, 2213-2227. https://doi.org/10.3892/or.2019.7364
MLA
Zi, F., Yu, L., Shi, Q., Tang, A., Cheng, J."Ibrutinib in CLL/SLL: From bench to bedside (Review)". Oncology Reports 42.6 (2019): 2213-2227.
Chicago
Zi, F., Yu, L., Shi, Q., Tang, A., Cheng, J."Ibrutinib in CLL/SLL: From bench to bedside (Review)". Oncology Reports 42, no. 6 (2019): 2213-2227. https://doi.org/10.3892/or.2019.7364